309 related articles for article (PubMed ID: 11122135)
1. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
Kröger N; Renges H; Krüger W; Gutensohn K; Löliger C; Carrero I; Cortes L; Zander AR
Br J Haematol; 2000 Dec; 111(3):761-5. PubMed ID: 11122135
[TBL] [Abstract][Full Text] [Related]
2. Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors.
Kröger N; Renges H; Sonnenberg S; Krüger W; Gutensohn K; Dielschneider T; Cortes-Dericks L; Zander AR
Bone Marrow Transplant; 2002 May; 29(9):727-30. PubMed ID: 12040468
[TBL] [Abstract][Full Text] [Related]
3. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
4. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
[TBL] [Abstract][Full Text] [Related]
5. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors.
Martínez C; Urbano-Ispizua A; Marín P; Merino A; Rovira M; Carreras E; Montserrat E
Bone Marrow Transplant; 1999 Dec; 24(12):1273-8. PubMed ID: 10627634
[TBL] [Abstract][Full Text] [Related]
7. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
[TBL] [Abstract][Full Text] [Related]
8. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.
Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM
Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors.
Suzuya H; Watanabe T; Nakagawa R; Watanabe H; Okamoto Y; Onishi T; Abe T; Kawano Y; Kagami S; Takaue Y
Vox Sang; 2005 Nov; 89(4):229-35. PubMed ID: 16262756
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial to compare once- versus twice-daily filgrastim for mobilization of peripheral blood stem cells from healthy donors.
Komeno Y; Kanda Y; Hamaki T; Mitani K; Iijima K; Ueyama J; Yoshihara S; Yuji K; Kim SW; Ando T; Kami M; Yamamoto E; Hiruma K; Mori S; Hirai H; Sakamaki H;
Biol Blood Marrow Transplant; 2006 Apr; 12(4):408-13. PubMed ID: 16545724
[TBL] [Abstract][Full Text] [Related]
11. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
12. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
14. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
[TBL] [Abstract][Full Text] [Related]
15. [Randomized clinical study for two types of recombinant human granulocyte colony-stimulating factor mobilizing peripheral blood and bone marrow stem cells in patients receiving allogeneic hematopoietic stem cell transplantation].
Zhang XH; Huang XJ; Liu DH; Liu KY; Han W; Chen H; Wang FR; Chen YH; Wang JZ; Zhao T; Wang Y; Xu LP
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2116-9. PubMed ID: 20058615
[TBL] [Abstract][Full Text] [Related]
16. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.
Kroschinsky F; Hölig K; Poppe-Thiede K; Zimmer K; Ordemann R; Blechschmidt M; Oelschlaegel U; Bornhauser M; Rall G; Rutt C; Ehninger G
Haematologica; 2005 Dec; 90(12):1665-71. PubMed ID: 16330441
[TBL] [Abstract][Full Text] [Related]
17. Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study.
Beelen DW; Ottinger H; Kolbe K; Pönisch W; Sayer HG; Knauf W; Stockschläder M; Scheid C; Schaefer UW
Ann Hematol; 2002 Dec; 81(12):701-9. PubMed ID: 12483366
[TBL] [Abstract][Full Text] [Related]
18. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
[TBL] [Abstract][Full Text] [Related]
20. A randomised study of 10 microg/kg/day (single dose) vs 2 x 5 microg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients.
Carrión R; Serrano D; Gómez-Pineda A; Díez-Martín JL
Bone Marrow Transplant; 2003 Sep; 32(6):563-7. PubMed ID: 12953127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]